<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="102550">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01958060</url>
  </required_header>
  <id_info>
    <org_study_id>1312.1</org_study_id>
    <secondary_id>2011-004615-23</secondary_id>
    <nct_id>NCT01958060</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of Single Escalating Doses of BI 1034020 Administered Intravenously or Subcutaneously to Male Healthy Volunteers</brief_title>
  <official_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Intravenous and Subcutaneous Doses of BI 1034020 in Healthy Male Volunteers (Partially Randomised, Single-blind, Placebo-controlled Within Dose Groups, Clinical Phase I Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigation of safety and tolerability of BI 1034020 in healthy male volunteers following
      intravenous (IV) infusion of subcutaneous (SC) injection of single doses and exploration of
      the pharmacokinetics and pharmacodynamics of BI 1034020 after single dosing and
      determination of the bioavailability of subcutaneous injections of BI 1034020
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of subjects (%) with drug related adverse events</measure>
    <time_frame>up to 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum measured concentration of the analyte in plasma)</measure>
    <time_frame>up to 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-8 (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)</measure>
    <time_frame>up to 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-tz (area under the concentration-time curve of the analyte in the plasma over the time interval from 0 to the last measurable time point of the dose)</measure>
    <time_frame>up to 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BI 1034020 intravenous part</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single rising doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 1034020 subcutaneous part</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single rising doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1034020</intervention_name>
    <description>intravenous part</description>
    <arm_group_label>BI 1034020 intravenous part</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1034020</intervention_name>
    <description>subcutaneous part</description>
    <arm_group_label>BI 1034020 subcutaneous part</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to BI 1034020</intervention_name>
    <description>intravenous part</description>
    <arm_group_label>BI 1034020 intravenous part</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to BI 1034020</intervention_name>
    <description>subcutaneous part</description>
    <arm_group_label>BI 1034020 subcutaneous part</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Healthy males based upon a complete medical history, including a physical
             examination, vital signs (blood pressure, pulse rate), 12-lead electrocardiogram, and
             clinical laboratory tests

          2. Age within the range of 18 to 40 years

          3. Body mass index within the range of 18.5 and 29.9 kg/m2

          4. Signed and dated written informed consent prior to admission to the study in
             accordance with GCP and local legislation.

        Exclusion criteria:

          1. Any finding in the medical examination (including blood pressure, pulse rate or
             electrocardiogram) deviating from normal and judged clinically relevant by the
             investigator. Pulse rate outside the range of 50-90 bpm or blood pressure outside the
             ranges of 90-140 for systolic and 50-90 mmHg for diastolic blood pressure if
             confirmed by repeat measurement

          2. Any evidence of a clinically relevant concomitant disease.

          3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders.

          4. Surgery of the gastrointestinal tract (except appendectomy).

          5. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders.

          6. History of relevant orthostatic hypotension, fainting spells or blackouts.

          7. Chronic or relevant acute infections.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1312.1.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Biberach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1312.1.2 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ingelheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1312/1312.1_statement.pdf</url>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 28, 2014</lastchanged_date>
  <firstreceived_date>October 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
